eHealth, Inc. (EHTH)

Q: What's priced into eHealth, Inc. (EHTH) stock?

The valuation evidence points to EHTH being cheap versus peers, with a small peer premium also reported, so the relative valuation signal is mixed. The expectations gap is slightly negative, but model confidence is low; the evidence does not support a firm conclusion about what the market already assumes.

Q: What does the eHealth, Inc. (EHTH) outlook hinge on?

The multi-year thesis hinges on whether management delivers the stated savings and sustains better cash flow while improving financial performance. Near term, a guidance cut would be a meaningful negative; stable guidance and continued cost progress would support the turnaround case. Rate moves and results from sector bellwethers are additional sector-level swing factors.

NASDAQFinancialsInsurance - BrokersSnapshot 2026-10-23

$0.53-3.22%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge eHealth, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	274.23M
EPS	—	2.503
FY 2026 · Annual
Revenue	$405M–$445M	422.25M
EPS	—	0.668
EBITDA	$55M–$75Mnon-GAAP	—
Operating cash flow	-$10M–$12M	—
FY 2027 · Annual
Revenue	—	434.36M
EPS	—	0.756

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Achieve $30M fixed cost savings and $60M variable spend reduction in 2026	A primary condition in eHealth, Inc.'s published investment case. The stated target is $30M fixed + $60M variable cost savings.	Under Pressure	cost savings fall short of $90M total in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Operating margin improves to near breakeven in FY26	A primary condition in eHealth, Inc.'s published investment case. The stated target is operating margin around 1% (mid guidance).	Broken	operating margin remains below -10% in FY26	Operating margin: -81.8% FY2026-Q2; GAAP. Published target: operating margin around 1% (mid guidance). Target period is not explicitly aligned with this observation. Source published Aug 5, 2026-81.800036 percent · calculatedSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 0c15a1ed-82f2-4f59-aa0d-524766ba20e2. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Maintain revenue between $405M and $445M in FY26	A primary condition in eHealth, Inc.'s published investment case. The stated target is >= $405M and <= $445M.	Intact	revenue falls below $405M or above $445M in FY26	Revenue: $33.566M FY2026-Q2; GAAP. Published target: >= $405M and <= $445M. Target period is not explicitly aligned with this observation. Source published Aug 5, 202633,566,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 0c15a1ed-82f2-4f59-aa0d-524766ba20e2. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated in 2 of 2 supplied quarters. Q2 revenue was $33.6 million versus $60.8 million in Q2 2025, while management reiterated full-year 2026 guidance of $405.0 million to $445.0 million. The quarterly revenue decline makes progress toward the annual outlook difficult to establish from the supplied results, so delivery against the reiterated guidance is not yet demonstrated. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenueUnavailable

Unavailable → Unavailable · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	3 / 4
2026-07-25	Unavailable	$447,346,060	4 / 5
2026-07-26	Unavailable	Unavailable	3 / 4
2026-07-27	Unavailable	$447,346,060	4 / 5
2026-07-28	Unavailable	$447,346,060	4 / 5
2026-07-29	Unavailable	$447,346,060	4 / 5
2026-07-30	Unavailable	$447,346,060	4 / 5
2026-07-31	Unavailable	Unavailable	3 / 4
2026-08-01	Unavailable	Unavailable	3 / 4
2026-08-02	Unavailable	$447,346,060	4 / 5
2026-08-03	Unavailable	$447,346,060	4 / 5
2026-08-04	Unavailable	Unavailable	3 / 4
2026-08-05	Unavailable	$447,346,060	4 / 5
2026-08-06	Unavailable	Unavailable	3 / 4
2026-08-07	Unavailable	Unavailable	3 / 4
2026-08-08	Unavailable	$436,894,180	3 / 5
2026-08-09	Unavailable	$436,894,180	3 / 5
2026-08-10	Unavailable	$436,894,180	3 / 5
2026-08-11	Unavailable	Unavailable	3 / 4
2026-08-12	Unavailable	Unavailable	3 / 4
2026-08-13	Unavailable	$436,894,180	3 / 5
2026-08-14	Unavailable	Unavailable	3 / 4
2026-08-15	Unavailable	Unavailable	2 / 4
2026-08-16	Unavailable	Unavailable	2 / 4
2026-08-17	Unavailable	Unavailable	2 / 4
2026-08-18	Unavailable	Unavailable	2 / 4
2026-08-19	Unavailable	Unavailable	2 / 4
2026-08-20	Unavailable	Unavailable	2 / 4
2026-08-21	Unavailable	Unavailable	2 / 4
2026-08-22	Unavailable	Unavailable	2 / 4
2026-08-23	Unavailable	Unavailable	2 / 4
2026-08-24	Unavailable	Unavailable	2 / 4
2026-08-25	Unavailable	Unavailable	2 / 4
2026-08-26	Unavailable	Unavailable	2 / 4
2026-08-27	Unavailable	Unavailable	2 / 4
2026-08-28	Unavailable	Unavailable	2 / 4
2026-08-29	Unavailable	Unavailable	2 / 4
2026-08-30	Unavailable	Unavailable	2 / 4
2026-08-31	Unavailable	Unavailable	2 / 4
2026-09-01	Unavailable	Unavailable	2 / 4
2026-09-02	Unavailable	Unavailable	2 / 4
2026-09-03	Unavailable	Unavailable	2 / 4
2026-09-04	Unavailable	Unavailable	2 / 4
2026-09-05	Unavailable	Unavailable	2 / 4
2026-09-06	Unavailable	Unavailable	2 / 4
2026-09-07	Unavailable	Unavailable	2 / 4
2026-09-08	Unavailable	Unavailable	2 / 4
2026-09-09	Unavailable	Unavailable	2 / 4
2026-09-10	Unavailable	Unavailable	2 / 4
2026-09-11	Unavailable	Unavailable	2 / 4
2026-09-12	Unavailable	Unavailable	2 / 4
2026-09-13	Unavailable	Unavailable	2 / 4
2026-09-14	Unavailable	Unavailable	2 / 4
2026-09-15	Unavailable	Unavailable	2 / 4
2026-09-16	Unavailable	Unavailable	2 / 4
2026-09-17	Unavailable	Unavailable	2 / 4
2026-09-18	Unavailable	Unavailable	2 / 4
2026-09-19	Unavailable	Unavailable	2 / 4
2026-09-20	Unavailable	Unavailable	2 / 4
2026-09-21	Unavailable	Unavailable	2 / 4
2026-09-22	Unavailable	Unavailable	2 / 4
2026-09-23	Unavailable	Unavailable	2 / 4
2026-09-24	Unavailable	Unavailable	2 / 4
2026-09-25	Unavailable	Unavailable	2 / 4
2026-09-26	Unavailable	Unavailable	2 / 4
2026-09-27	Unavailable	Unavailable	2 / 4
2026-09-28	Unavailable	Unavailable	2 / 4
2026-09-29	Unavailable	Unavailable	2 / 4
2026-09-30	Unavailable	Unavailable	2 / 4
2026-10-01	Unavailable	Unavailable	2 / 4
2026-10-02	Unavailable	Unavailable	2 / 4
2026-10-03	Unavailable	Unavailable	2 / 4
2026-10-04	Unavailable	Unavailable	2 / 4
2026-10-05	Unavailable	Unavailable	2 / 4
2026-10-06	Unavailable	Unavailable	2 / 4
2026-10-07	Unavailable	Unavailable	2 / 4
2026-10-08	Unavailable	Unavailable	2 / 4
2026-10-09	Unavailable	Unavailable	2 / 4
2026-10-10	Unavailable	Unavailable	2 / 4
2026-10-11	Unavailable	Unavailable	2 / 4
2026-10-12	Unavailable	Unavailable	2 / 4
2026-10-13	Unavailable	Unavailable	2 / 4
2026-10-14	Unavailable	Unavailable	2 / 3
2026-10-15	Unavailable	Unavailable	2 / 3
2026-10-16	Unavailable	Unavailable	1 / 3
2026-10-17	Unavailable	Unavailable	1 / 3
2026-10-18	Unavailable	Unavailable	1 / 3
2026-10-19	Unavailable	Unavailable	1 / 3
2026-10-20	Unavailable	Unavailable	1 / 3
2026-10-21	Unavailable	Unavailable	1 / 3
2026-10-22	Unavailable	Unavailable	1 / 3
2026-10-23	Unavailable	Unavailable	1 / 3
2026-10-24	Unavailable	Unavailable	1 / 3

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	0	5	0
2026-06-01	0	5	0
2026-07-01	0	5	0
2026-08-01	0	5	0
2026-09-01	0	5	0
2026-10-01	0	5	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 0 Buy / Strong Buy · 5 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Achieve $30M fixed cost savings and $60M variable spend reduction in 2026Published status: Under Pressure
Operating margin improves to near breakeven in FY26Published status: Broken
Maintain revenue between $405M and $445M in FY26Revenue: $33.566M

Next proof point

Nov 4, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.8%Typical daily move · historical

Downside history

-90.6%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

eHealth, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a high-risk turnaround thesis, not a durable compounder today. The long-term thesis remains on watch: cost and cash-flow measures are improving, but recent performance is weak and the next earnings result carries elevated miss risk.

What's priced into eHealth, Inc.

The valuation evidence points to EHTH being cheap versus peers, with a small peer premium also reported, so the relative valuation signal is mixed. The expectations gap is slightly negative, but model confidence is low; the evidence does not support a firm conclusion about what the market already assumes.

What the fundamentals likely do

Near term, repeated earnings misses, the October 16 listing-rule notice, and a stated elevated risk of another miss weigh on the operating picture. There is progress on cost control and cash flow: Q2 operating costs were lower year over year, and operating cash flow improved, though full-year guidance still includes negative cash flow and the savings goals are not yet fully proven as realized results.

What eHealth, Inc. hinges on